Pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study.
Adult
Aged
Antineoplastic Agents
/ administration & dosage
Carcinoma, Ovarian Epithelial
/ pathology
Cisplatin
/ administration & dosage
Cytoreduction Surgical Procedures
/ adverse effects
Drug Resistance, Neoplasm
/ drug effects
Female
Humans
Hyperthermia, Induced
/ methods
Middle Aged
Ovarian Neoplasms
/ pathology
Prospective Studies
Cytoreduction Surgical Procedure
Endoscopy
Epithelial Ovarian Cancer
Injections, Intraperitoneal
Journal
Journal of gynecologic oncology
ISSN: 2005-0399
Titre abrégé: J Gynecol Oncol
Pays: Korea (South)
ID NLM: 101483150
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
07
09
2018
revised:
01
11
2018
accepted:
29
01
2019
pubmed:
11
5
2019
medline:
10
3
2020
entrez:
11
5
2019
Statut:
ppublish
Résumé
Evidences from animal models seem to suggest that minimally invasive surgery may enhance cisplatin diffusion when the drug is administered in the context of post-operative hyperthermic intraperitoneal chemotherapy (HIPEC). The present study evaluates the cisplatin pharmacokinetic profile in a prospective series of women with platinum sensitive recurrent epithelial ovarian cancer treated with open secondary cytoreductive surgery (O-SCS) or minimally-invasive secondary cytoreductive surgery (MI-SCS). Cisplatin levels were assessed at 0, 20, 40, 60, and 120 minutes in: 1) blood samples, 2) peritoneal perfusate, and 3) peritoneal biopsies at the end of HIPEC. Median C Nine (45.0%) women received MI-SCS, and 11 (55.0%) O-SCS. At 60 minutes, median cisplatin C We demonstrate for the first time that minimally invasive route enhances cisplatin peritoneal tissue uptake during HIPEC, further evaluations are needed to confirm the correlation between peritoneal cisplatin levels after HIPEC and survival. ClinicalTrials.gov Identifier: NCT01539785.
Identifiants
pubmed: 31074245
pii: 30.e59
doi: 10.3802/jgo.2019.30.e59
pmc: PMC6543101
doi:
Substances chimiques
Antineoplastic Agents
0
Cisplatin
Q20Q21Q62J
Banques de données
ClinicalTrials.gov
['NCT01539785']
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
e59Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2019. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology.
Déclaration de conflit d'intérêts
No potential conflict of interest relevant to this article was reported.
Références
Int J Cancer. 2002 May 1;99(1):130-7
pubmed: 11948504
Gynecol Oncol. 2004 Sep;94(3):650-4
pubmed: 15350354
Anticancer Drugs. 2005 Oct;16(9):1009-16
pubmed: 16162978
Ann Surg. 2006 Jul;244(1):106-12
pubmed: 16794395
Eur J Cancer. 2006 Sep;42(14):2296-302
pubmed: 16901687
Ann Surg Oncol. 2008 Jan;15(1):339-44
pubmed: 17943387
Ann Surg Oncol. 2008 Dec;15(12):3623-4
pubmed: 18726653
Oncology. 2008;75(3-4):152-8
pubmed: 18827492
Ann Surg Oncol. 2009 Apr;16(4):993-1000
pubmed: 19169758
Lancet. 2009 Oct 17;374(9698):1331-8
pubmed: 19767092
Ann Surg Oncol. 2012 Jul;19(7):2352-9
pubmed: 20039210
Cancer Chemother Pharmacol. 2011 Oct;68(4):1001-8
pubmed: 21327681
Gynecol Oncol. 2012 Dec;127(3):502-5
pubmed: 23022234
Gynecol Oncol. 2013 Oct;131(1):36-41
pubmed: 23791829
Ann Surg Oncol. 2014 Feb;21(2):553-9
pubmed: 24006094
Gynecol Oncol. 2014 Feb;132(2):303-6
pubmed: 24378877
Ann Surg Oncol. 2014 Oct;21(11):3621-7
pubmed: 24819120
Int J Cancer. 2015 Feb 1;136(3):699-708
pubmed: 24895230
J Minim Invasive Gynecol. 2015 Mar-Apr;22(3):428-32
pubmed: 25461683
Br J Cancer. 2015 Jan 20;112(2):306-12
pubmed: 25461804
Gynecol Oncol. 2015 May;137(2):223-8
pubmed: 25701703
Ann Surg Oncol. 2016 May;23(5):1660-5
pubmed: 26714958
Ann Surg Oncol. 2017 Apr;24(4):914-922
pubmed: 27896512
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Ann Surg Oncol. 2017 Jun;24(6):1650-1657
pubmed: 28160138
Eur J Surg Oncol. 2017 Nov;43(11):2178-2183
pubmed: 28964609
N Engl J Med. 2018 Jan 18;378(3):230-240
pubmed: 29342393
Cancer Res. 1973 Dec;33(12):3091-5
pubmed: 4760525
Ann Surg. 1995 Feb;221(2):124-32
pubmed: 7857141
Anticancer Drugs. 1996 Jul;7(5):596-603
pubmed: 8862729